Watch Hexima’s CEO, Mr Michael Aldridge, review the achievements of FY21 and inform investors of expected important developments and milestones. Hexima’s management appreciates the role that shareholders have played in the progress of the Company, and looks forward to updating attendees on the Company’s clinical and commercial progress.
View Investor Webinar recording here → Investor Review Recording